# EXELIXIS, INC. stock analysis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroi

## Market evidence and data freshness

The public preview recorded EXELIXIS, INC. at 58.37 USD on 2026-09-28T20:00:01.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2021-09-30 through 2026-09-18 across 1241 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

## What should I review before buying EXELIXIS, INC. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

## Inside the full report

- Valuation
- Growth
- Financial health
- Ownership
- Research

Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.

[Read the report](https://commonquant.ai/markets/exel)